Boston Scientific set to storm the US stent market with NIR approval
This article was originally published in Clinica
The FDA last week approved the sale of Boston Scientific's new range of NIR coronary stents. The stents are already market leaders in Europe and Japan and are expected to have a major impact on the US stent market within the first year of sales.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.